Compare Glenmark Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs WOCKHARDT - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA WOCKHARDT GLENMARK PHARMA/
WOCKHARDT
 
P/E (TTM) x 12.6 -13.7 - View Chart
P/BV x 1.8 1.1 170.1% View Chart
Dividend Yield % 0.6 0.0 15,344.6%  

Financials

 GLENMARK PHARMA   WOCKHARDT
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
WOCKHARDT
Mar-18
GLENMARK PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs7121,012 70.3%   
Low Rs484532 91.0%   
Sales per share (Unadj.) Rs349.6355.9 98.2%  
Earnings per share (Unadj.) Rs32.8-60.3 -54.4%  
Cash flow per share (Unadj.) Rs44.3-46.8 -94.8%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.30 25,828.3%  
Book value per share (Unadj.) Rs198.6257.8 77.1%  
Shares outstanding (eoy) m282.17110.63 255.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.2 78.8%   
Avg P/E ratio x18.2-12.8 -142.4%  
P/CF ratio (eoy) x13.5-16.5 -81.7%  
Price / Book Value ratio x3.03.0 100.5%  
Dividend payout %6.10 -36,775.5%   
Avg Mkt Cap Rs m168,62585,379 197.5%   
No. of employees `00012.06.3 192.5%   
Total wages/salary Rs m20,5619,371 219.4%   
Avg. sales/employee Rs Th8,196.06,295.0 130.2%   
Avg. wages/employee Rs Th1,708.11,498.3 114.0%   
Avg. net profit/employee Rs Th768.5-1,066.3 -72.1%   
INCOME DATA
Net Sales Rs m98,65539,369 250.6%  
Other income Rs m2,0811,202 173.1%   
Total revenues Rs m100,73640,571 248.3%   
Gross profit Rs m15,85818 86,656.4%  
Depreciation Rs m3,2591,495 218.0%   
Interest Rs m3,3462,555 131.0%   
Profit before tax Rs m11,335-2,830 -400.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-3,582 -46.7%   
Tax Rs m3,756257 1,461.6%   
Profit after tax Rs m9,250-6,669 -138.7%  
Gross profit margin %16.10 34,581.0%  
Effective tax rate %33.1-9.1 -364.9%   
Net profit margin %9.4-16.9 -55.4%  
BALANCE SHEET DATA
Current assets Rs m66,96833,796 198.2%   
Current liabilities Rs m40,21126,917 149.4%   
Net working cap to sales %27.117.5 155.2%  
Current ratio x1.71.3 132.6%  
Inventory Days Days8379 105.0%  
Debtors Days Days8189 91.0%  
Net fixed assets Rs m33,32239,664 84.0%   
Share capital Rs m282553 51.0%   
"Free" reserves Rs m55,77027,968 199.4%   
Net worth Rs m56,05228,522 196.5%   
Long term debt Rs m35,73821,731 164.5%   
Total assets Rs m132,88881,620 162.8%  
Interest coverage x4.4-0.1 -4,080.8%   
Debt to equity ratio x0.60.8 83.7%  
Sales to assets ratio x0.70.5 153.9%   
Return on assets %9.5-5.0 -188.1%  
Return on equity %16.5-23.4 -70.6%  
Return on capital %17.8-7.7 -232.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,9989,807 642.4%   
Fx outflow Rs m22,8591,789 1,278.0%   
Net fx Rs m40,1408,019 500.6%   
CASH FLOW
From Operations Rs m13,242684 1,934.8%  
From Investments Rs m-6,9906,302 -110.9%  
From Financial Activity Rs m-7,387-7,695 96.0%  
Net Cashflow Rs m-2,971-664 447.4%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 2.3 300.0%  
FIIs % 34.4 7.7 446.8%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   56,727 67,757 83.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FDC LTD.  UNICHEM LAB  PROCTER & GAMBLE HEALTH  BIOCON   ALEMBIC LTD  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - J.B.CHEMICALS COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS